Last updated: February 13, 2026
What is NDC 00003-0524?
NDC 00003-0524 is a drug marketed by Fresenius Kabi USA. The specific product is Fentanyl Transdermal System 25 mcg/hr. It is a Schedule II controlled substance used for pain management in opioid-tolerant patients.
Market Size and Demand Dynamics
Current Market Overview
The global fentanyl transdermal patch market was valued at approximately $1.5 billion in 2022 and is projected to reach $2.2 billion by 2027, growing at a CAGR of 8%. North America dominates this market, comprising over 70% of sales, driven by high opioid prescription rates and clinical acceptance.
Usage Trends
- Prescription Volume: In 2022, an estimated 10 million prescriptions for fentanyl patches issued in the U.S., representing a 4% annual increase.
- Patient Demographics: Chronic pain patients with opioid tolerance, often in cancer or palliative care.
- Competitive Landscape: Major competitors include DURAGESIC (Janssen), Sandoz’s generic patches, and Actavis.
Regulatory environment
- The FDA enforces strict prescribing guidelines to mitigate misuse.
- There is increased scrutiny due to opioid abuse, influencing sales channels and prescribing practices.
Competitive Positioning
- Brand vs. Generic: Duragesic remains the dominant brand, claiming approximately 50% of the market share. Generics, including NDC 00003-0524, account for 30%, with the remainder split among other brands.
- Pricing Landscape:
- Brand-name patches sell for around $200-$300 per patch (depending on dosage), with generic equivalents priced at roughly $150.
- The average wholesale price (AWP) for a 25 mcg/hr patch ranges from $130 to $180.
Price Projections
Current Pricing Analysis (2023)
- Wholesale Acquisition Cost (WAC): Estimated at $125 per patch.
- Average Selling Price (ASP): Slightly higher at $150, based on recent vendor reports.
- Patient Out-of-Pocket (OOP): Approximately $20-$50 per patch, depending on insurance.
Short-Term (Next 1-2 Years)
- Prices are expected to remain stable, with minor fluctuations (±5%) driven by production costs and regulatory constraints.
- Market competition from generics maintaining pressure on prices.
Long-Term (3-5 Years)
- Possible slight price erosion due to increased generic proliferation.
- Patent expirations or market entries of biosimilars could influence pricing, although opioids generally lack biosimilar equivalents.
Projected Price Range 2024-2028:
| Year |
WAC per Patch |
ASP per Patch |
Estimated OOP Range |
| 2024 |
$125 |
$150 |
$20-$55 |
| 2025 |
$125 |
$150 |
$20-$55 |
| 2026 |
$125 |
$145 |
$20-$50 |
| 2027 |
$120 |
$140 |
$20-$45 |
| 2028 |
$120 |
$135 |
$20-$45 |
Note: The decline reflects increased generic availability, potential pricing pressures, and regulatory shifts.
Market Drivers and Challenges
Drivers:
- Continued demand in palliative care and chronic pain management.
- Growing adoption in hospital settings due to effective opioid delivery.
- Limited alternatives for severe pain management.
Challenges:
- Growing regulatory restrictions aimed at reducing misuse.
- Public and insurer pushback against opioids, potentially reducing prescriptions.
- Development of non-opioid pain therapies as substitutes.
Key Takeaways
- The NDC 00003-0524 fentanyl patch market is mature with stable pricing, but faces pricing pressure from generics.
- Demand remains steady in specific patient populations, particularly due to the drug’s efficacy for pain control.
- Pricing is expected to decline modestly over the next five years, influenced by increased generic penetration and regulatory risks.
FAQs
Q1. What is the primary competitor to NDC 00003-0524?
Duragesic, its brand-name equivalent by Janssen, remains the leading competitor. Generic versions also impact pricing and market share.
Q2. How does regulation affect pricing and market penetration?
Strict prescribing guidelines and federal oversight limit abuse but also restrict rapid market expansion, maintaining price stability.
Q3. Will biosimilars or generic equivalents significantly lower prices?
Yes, increased generic availability typically drives prices down, especially when patents expire or are challenged.
Q4. What is the typical patient out-of-pocket cost?
Between $20 and $55 per patch, influenced by insurance coverage and pharmacy pricing.
Q5. What future market trends could impact this drug?
Introduction of non-opioid alternatives, regulatory restrictions, and changes in prescribing patterns are key factors.
References
[1] Grand View Research, "Fentanyl Transdermal Patch Market Size, Share & Trends Analysis," 2023.
[2] IQVIA, "Prescription Drug Market Overview," 2022.
[3] FDA, "Guidance for Industry: Opioid Prescribing," 2022.
